{"disease":{"id":"malignant-primary-gliomas","name":"malignant primary gliomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06630260","title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":182,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT07391215","title":"5G-PEARL: Paxalisib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT06632236","title":"5G-EMERALD: Amivantamab in Malignant Brain Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}